Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2020 16:30 ET | Source: Passage Bio

Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares

PHILADELPHIA, March 09, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
March 05, 2020 08:00 ET | Source: Passage Bio

Passage Bio Appoints Athena Countouriotis to Board of Directors

PHILADELPHIA, March 05, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...
February 27, 2020 19:24 ET | Source: Passage Bio

Passage Bio Announces Pricing of Initial Public Offering

PHILADELPHIA, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders...
January 28, 2020 08:00 ET | Source: Passage Bio

Passage Bio Appoints Bruce Goldsmith, Ph.D. as Chief Executive Officer

PHILADELPHIA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with...
January 10, 2020 08:00 ET | Source: Passage Bio

Passage Bio Appoints Sandip Kapadia to Board of Directors

PHILADELPHIA, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today...
November 27, 2019 08:00 ET | Source: Passage Bio

Passage Bio to Present at Piper Jaffray 31st Annual Healthcare Conference

PHILADELPHIA, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system diseases, today...
November 06, 2019 08:00 ET | Source: Passage Bio

Passage Bio to Present at Barclays Gene Editing & Gene Therapy Summit

PHILADELPHIA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
October 29, 2019 08:00 ET | Source: Passage Bio

Passage Bio Appoints Richard Morris as Chief Financial Officer

PHILADELPHIA, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
September 25, 2019 08:00 ET | Source: Passage Bio

Passage Bio to Present at Upcoming Investor Conferences

PHILADELPHIA, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...
September 23, 2019 08:00 ET | Source: Passage Bio

Passage Bio Grows Management Team with Chief Medical Officer and General Counsel Appointments

PHILADELPHIA, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system diseases,...